Satumomab
Alternative Names: CYT 103; Indium 111In-satumomab pendetide; OncoScint CR/OV; OncoScint CR103; OncoScint OV103; satumomab pendetideLatest Information Update: 14 May 2008
At a glance
- Originator Cytogen Corporation
- Class Acetic acids; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Monoclonal antibody diagnostics; Oligopeptides; Polyamines; Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; Ovarian cancer
Most Recent Events
- 09 May 2008 Cytogen Corporation is acquired by EUSA Pharma
- 31 Aug 2004 Aventis merges with Sanofi-Synthelabo to form Sanofi-Aventis
- 31 Dec 2002 Cytogen discontinues selling satumomab